Evaxion's Breakthrough in Cancer Vaccine Development
Evaxion A/S (NASDAQ: EVAX), a pioneering clinical-stage TechBio company, has made remarkable strides in the field of cancer immunotherapy with its AI-designed personalized cancer vaccine, EVX-01. Recently, the company reported groundbreaking results from a Phase 2 trial, which highlighted an impressive objective response rate (ORR) of 75% in advanced melanoma patients.
Impressive Clinical Efficacy Data
According to the trial results, 12 out of 16 patients demonstrated objective clinical responses to EVX-01. This achievement is significant, especially considering the fact that four of these patients achieved complete response status. The data exhibited that the ORR increased from 69% after one year of treatment to an astounding 75% after two years, showing the potential durability of the vaccine's effects.
Durable Responses and High Tolerability
In addition to the impressive response rates, the data also revealed that a remarkable 92% of patients continued to show signs of response at the 24-month follow-up mark. Particularly noteworthy is that 54% of patients experienced a deepened response, transitioning from stable disease or partial response to either partial or complete response. This suggests that EVX-01 not only initiates responses but also enhances them over time, providing hope for stronger long-term outcomes.
Broad Immune Activation Observed
Furthermore, the results from this trial underscored the immune activation capabilities generated by EVX-01. Immune responses were noted in all the participants, with an impressive 81% of the vaccine's targeted neoantigens eliciting specific T-cell reactions. This level of immunogenicity is a significant indicator of the vaccine's efficacy and illustrates the precise targeting capabilities of Evaxion’s AI-Immunology™ platform, which devises personalized vaccines on a patient-by-patient basis.
Safety and Future Discussions
The treatment was reported to be well tolerated among participants, supporting the design's safety profile. Following the announcement, Evaxion’s Chief Scientific Officer, Birgitte Rønø, expressed enthusiasm regarding the data, highlighting its unprecedented ORR as a promising indication of EVX-01's potential as an innovative treatment option for challenging cases of melanoma. Rønø emphasized the importance of collaboration for further clinical development, which will hinge on partnerships as the company navigates its path forward.
Expert Commentary on Study Outcomes
Professor Muhammad Adnan Khattak, an oncology expert and key opinion leader, plans to delve deeper into the trial's findings during an upcoming webinar. He acknowledges that these long-term efficacy results may very well redefine benchmarks for personalized immunotherapy, showcasing the clinical significance of Evaxion's innovative approach to cancer vaccine development.
Trial Design and Future Outlook
The Phase 2 trial specifically sought to investigate EVX-01 in conjunction with MSD’s anti-PD-1 treatment known as KEYTRUDA (pembrolizumab). Each participant received a vaccine uniquely tailored to their individual biological makeup, emphasizing the advantages of personalized medicine in oncology. Newly, the trial's design has been extended with an additional year of treatment where participants will receive EVX-01 as monotherapy. Anticipation builds for additional data, which will be revealed in 2026.
About EVX-01 and Evaxion
EVX-01 is Evaxion's flagship personalized peptide-based cancer vaccine, specifically aimed at the first-line treatment of advanced solid tumors. Developed via the company’s cutting-edge AI-Immunology™ platform, EVX-01 not only targets unique tumor antigens but also galvanizes the patient's immune response to effectively combat cancer. Evaxion prides itself on its innovative approach to harnessing AI technology to transform the treatment landscape for various diseases.
Contact Evaxion for More Information
If you are interested in learning more about Evaxion’s ongoing research or the promising developments surrounding EVX-01, you can reach out to:
Mads Kronborg
Vice President, Investor Relations & Communication
Contact Number: +45 53 54 82 96
Email: mak@evaxion.ai
Frequently Asked Questions
What is EVX-01?
EVX-01 is a personalized cancer vaccine developed by Evaxion targeting advanced melanoma and other solid tumors.
What were the results of the Phase 2 trial?
The trial showed a 75% objective response rate, with significant durability of responses observed at 24 months.
Who conducted the trial?
The trial was conducted by Evaxion A/S in collaboration with MSD's anti-PD-1 therapy, KEYTRUDA.
What does the future hold for EVX-01?
Further clinical development is planned, with additional results expected in 2026 from extended treatment protocols.
How can I learn more about Evaxion?
For more information about Evaxion and its innovative solutions, please contact the Investor Relations team or visit their official website.
